MarketPulse

TIL therapy

2 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Iovance's Cell Therapy Bet: $1B Revenue Dream Amid Manufacturing Headwinds

Iovance's Amtagvi cancer therapy targets $1B+ revenue by 2030 amid strong early growth, but faces manufacturing cost and regulatory risks.
IOVAbiotechoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Iovance Grants Stock Options to New Employees Under NASDAQ Inducement Plan

Iovance granted 3,600 stock options to two new employees at $2.85/share under NASDAQ inducement plan rules, with three-year vesting.
IOVAvesting schedulebiotechnology